Information Provided By: 
Fly News Breaks for June 13, 2018
SAGE
Jun 13, 2018 | 07:50 EDT
Canaccord analyst Sumant Kulkarni raised his price target on Sage Therapeutics to $220 from $210 after the company announced it had a positive breakthrough meeting with the FDA on Sage-217, an oral drug being developed for postpartum depression, major depressive disorder and other psychiatric indications. Kulkarni believes the MDD indication is the main stock driver and he views the developments as very encouraging. Kulkarni reiterated his Buy rating on Sage shares.
News For SAGE From the Last 2 Days
There are no results for your query SAGE
